1-3 of 3
Anna D.D. van Muyden
Close
Sort by
Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Marie José Kersten, Kirsten Saevels, Yves Beguin, Joost S.P Vermaat, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille
Journal: Blood
Blood (2023) 142 (Supplement 1): 2113.
https://doi.org/10.1182/blood-2023-172736
Published: 2023
Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Natalia Tovar, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Sergi Betriu, Daniel Esteban, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden
Journal: Blood
Blood (2023) 142 (Supplement 1): 2112.
https://doi.org/10.1182/blood-2023-189321
Published: 2023
Journal Articles

Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma

Niels W.C.J. van de Donk, Sébastien Anguille, Jo Caers, Marte C. Liefaard, Christian Jacques, Anna D.D. van Muyden
Journal: Blood
Blood (2023) 142 (Supplement 1): 4859.
https://doi.org/10.1182/blood-2023-189001
Published: 2023